ClinicalTrials.gg
RecruitingNCT07313592Updated Oct 9, 2026

Whole Genome Sequencing (ChromoSeq®) for Acute Lymphoblastic Leukemia (ALL) Patients

An observational study in Acute Lymphoblastic Leukemia, sponsored by Washington University School of Medicine. Recruiting at 1 site in United States. Open to participants aged Up to 30 Years. Per ClinicalTrials.gov, last updated 2026-10-09.

Sponsored by Washington University School of Medicine · Observational

How we know

From the registry’s dates

  • Started Jun 2026; still recruiting 5 months later.
Updated Oct 9, 2026Now RecruitingSite recruiting status changed+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
60
Ages
Up to 30 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 15 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma by Washington University School of Medicine — 2 open to participants now, 3 under way, none of them phase 3. Precursor Cell Lymphoblastic Leukemia-Lymphoma · Washington University School of Medicine.

Started
2026
with 1 other
Observational
Only one
of the 15
Registered
14th of 15
by date

Among the 15 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma by Washington University School of Medicine, this one is one of 2 that started in 2026, is the only observational one, and was the 14th registered.

Precursor Cell Lymphoblastic Leukemia-Lymphoma

2,586 studies on the registry are indexed under Precursor Cell Lymphoblastic Leukemia-Lymphoma; 471 are open to participants now.

Browse Precursor Cell Lymphoblastic Leukemia-Lymphoma studies →

Open to participants now

2 of the 15 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma by Washington University School of Medicine are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 369 Precursor Cell Lymphoblastic Leukemia-Lymphoma studies recruiting now, 96 (26%) set no upper age limit and 257 (70%) stop at 75 or younger; 247 take children under 18; 29 take healthy volunteers.

This study: Up to 30 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma by Washington University School of Medicine, or all of them as a file.
02

Study summary

This is a prospective data collection study evaluating the feasibility of using the ChromoSeq® assay for upfront classification in a real-time clinical setting of pediatric and young patients suspected of having ALL. Sixty patients will undergo collections of bone marrow and/or peripheral blood for the ChromoSeq® assay at time of initial workup as part of standard of care, and the patients will then be followed for clinical outcomes for up to 65 months.

03

Conditions studied

  • Acute Lymphoblastic Leukemia

Keywords

  • Acute Lymphoblastic Leukemia
  • B-ALL
  • T-ALL
  • Next generation sequencing
  • Pediatric
04

Who can participate

Ages eligible
Up to 30 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Child and young adult patients with suspected diagnosis or suspected relapse acute lymphoid leukemia (ALL) seen at St. Louis Children's Hospital/Washington University School of Medicine.

Eligibility criteria

Eligibility Criteria

  • Children and young adult patients (\< 30 years of age at time of study enrollment) treated at St. Louis Children's Hospital/Washington University School of Medicine.
  • Suspected diagnosis or suspected relapse of acute lymphoblastic leukemia (ALL), B- or T-cell.
  • Concurrent enrollment on a prospective therapeutic trial is allowed as this protocol makes no recommendations regarding treatment approach.
  • Ability to understand and willingness to sign an IRB approved written document. All patients and/or their parents or legal guardians must sign an IRB approved written informed consent document.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
60 participants (estimated)
Patient registry
No

Groups and cohorts

  • Child and Young Adult acute lymphoid leukemia (ALL) patients

    Data collection will include patient and disease related characteristics such as demographic information, relevant medical history, ALL classification, diagnosis information, treatment, treatment response, recurrence data, and transplant data. Specific clinical data points collected will include ChromoSeq® testing results, minimal residual disease testing results at 8 days into treatment, end of induction (28 days into treatment) and end of consolidation if applicable (\~3 months into treatment), and time of any relapses from time of diagnosis.

06

What researchers measure

Primary outcomes

  1. Rate of success of ChromoSeq®

    ChromoSeq® will be successful if the results on the first attempt in a real-time, clinical setting identifies recurrent structural variants and copy number alterations of conventional cytogenetics and karyotype. The success rate and the 95% confidence interval will be calculated.

    Time frame: Time of specimen collection to completion of results (total estimated time is 15 days)

Secondary outcomes

  1. Comparison of time-to-results of ChromoSeq® and conventional cytogenetics

    The proportion of results return within 15 days and the 95% confidence interval will be calculated.

    Time frame: Time of specimen collection to 15 days after collection (total estimated time is 15 days)

  2. Frequency of mismatch between LDA standard testing and ChromoSeq® defined Ph-like patients.

    The outcome will be measured by determining the correlation of LDA testing on patients with neutral cytogenetics versus LDA testing on patients whose ChromoSeq® results display a Ph-like translocation for validation.

    Time frame: Time of specimen collection to completion of LDA testing (total estimated time is 15 days)

07

Study locations

1 of 1 sites recruiting
  • Washington University School of Medicine/St. Louis Children's Hospital
    St Louis, Missouri 63110, United States
    Recruiting
    • Margaret Ferris, MD, PhD · Contactyoungm@wustl.edu · 314-454-6018
    • Margaret Ferris, MD, PhD · Principal investigator
    • Feng Gao, PhD · Sub investigator
08

References and documents

Individual participant data

Plan to share: Yes — All of the individual participant data collected during the trial, after de-identification.

Supporting information: Study protocol

Time frame: Immediately following publication. No end date.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Jul 2028, 25 months after the start.

Of 145 non-industry observational studies under Precursor Cell Lymphoblastic Leukemia-Lymphoma, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 143. This study's planned 25 months is below that.

Counting every sponsor, half of 163 studies reached it within 49 months; a quarter within 22 and three quarters within 142.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 17, 2025
First posted
Jan 2, 2026
StartActual
Jun 3, 2026
Primary completionEst.
Jul 15, 2028
CompletionEst.
Jul 15, 2028
Last update
Oct 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Suspended→Recruiting Reason for stopping removed
changed Oct 9, 2026
Sites
Washington University School of Medicine/St. Louis Children's Hospital is now Recruiting
Oct 9, 2026
Eligibility
Revised
Oct 9, 2026
Interventions
Arms or interventions changed
Oct 9, 2026
Contact
Study contact now listed: added y•••@wustl.edu · •••6018. See the current contact
Oct 9, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Washington University School of Medicine/St. Louis Children's Hospital · St Louis, United StatesContact added y•••@wustl.edu · •••6018Contact added (no phone or email listed)Contact added (no phone or email listed)
Oct 9, 2026
Show all 1 update
  1. Oct 9, 2026
    Suspended→Recruiting
    Why stopped Reason for stopping removed
    Washington University School of Medicine/St. Louis Children's Hospital is now Recruiting
    Eligibility Revised
    Interventions Arms or interventions changed
    Contact Study contact now listed: added y•••@wustl.edu · •••6018. See the current contact
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Washington University School of Medicine/St. Louis Children's Hospital · St Louis, United StatesContact added y•••@wustl.edu · •••6018Contact added (no phone or email listed)Contact added (no phone or email listed)
    + 5 other changes: verification date, oversight details, description, design details and data sharing statement

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07313592
Collaborators
McDonnell Center
Responsible party
Sponsor
First posted
Jan 2, 2026
Start date
Jun 3, 2026
Primary completion
Jul 15, 2028 (estimated)
Completion
Jul 15, 2028 (estimated)
Last update
Oct 9, 2026

Study contacts

Margaret Ferris, MD, PhD
Contact
youngm@wustl.edu
314-454-6018
Margaret Ferris, MD, PhD
principal investigator · Washington University School of Medicine

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion